Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has earned an average recommendation of “Hold” from the ten analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.63.

Several research analysts recently commented on ACHN shares. Leerink Swann reiterated a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. BidaskClub upgraded Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Finally, Zacks Investment Research cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up $0.02 during trading hours on Friday, hitting $2.70. The company had a trading volume of 495,825 shares, compared to its average volume of 1,648,083. Achillion Pharmaceuticals has a fifty-two week low of $2.58 and a fifty-two week high of $5.66. The firm has a market capitalization of $369.46, a PE ratio of -5.55 and a beta of 1.32.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.24% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in ACHN. SG Americas Securities LLC increased its holdings in Achillion Pharmaceuticals by 59.8% in the third quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 15,800 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Achillion Pharmaceuticals by 53.8% during the second quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 15,000 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Achillion Pharmaceuticals by 13.7% during the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 6,730 shares during the last quarter. UBS Asset Management Americas Inc. grew its holdings in shares of Achillion Pharmaceuticals by 18.6% during the second quarter. UBS Asset Management Americas Inc. now owns 63,669 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Matisse Capital grew its holdings in shares of Achillion Pharmaceuticals by 15.8% during the fourth quarter. Matisse Capital now owns 135,445 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 18,500 shares during the last quarter. 76.78% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Analysts Set Achillion Pharmaceuticals, Inc. (ACHN) Price Target at $5.63” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2018/02/05/analysts-set-achillion-pharmaceuticals-inc-achn-price-target-at-5-63.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.